Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: Integrated nomogram based on five stage-related genes and TNM stage to predict 1-year recurrence in hepatocellular carcinoma

Fig. 5

ROC curve analysis, DCA and clinical impact curve analysis in the training cohort, the testing cohort and the external validation cohort. a–c Comparisons of the predictive value of the nomogram (orange), TNM stage (blue) and RS (green) for 1-year recurrence according to ROC analysis. ROC curves in the training cohort (a), the testing cohort (b) and the external validation cohort (c). The AUC and 95% CI were calculated. df DCA of the nomogram (red) and TNM stage (blue) for predicting 1-year recurrence in the training cohort (d), the testing cohort (e) and the external validation cohort (f). The X axis shows the high-risk threshold, and the Y axis represents the standardized net benefit. g–i Clinical impact curves of the nomogram for predicting 1-year recurrence in the training cohort (g), the testing cohort (h) and the external validation cohort (i). The number of high-risk patients (black dotted line) and the number of high-risk patients with events (red solid line) are plotted

Back to article page